Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43858   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2009-011003-23
    Sponsor's Protocol Code Number:GFT505-209-4
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2009-03-25
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2009-011003-23
    A.3Full title of the trial
    A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.
    A.4.1Sponsor's protocol code numberGFT505-209-4
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGENFIT
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGFT505 20mg lactose - magnesium stearate
    D.3.2Product code GFT505
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 824932-88-9
    D.3.9.2Current sponsor codeGFT505
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    patients presenting with impaired glucose tolerance and abdominal obesity
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10036481
    E.1.2Term Pre-diabetes
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10059179
    E.1.2Term Abdominal obesity
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of GFT505 80mg compared with placebo in improving Oral Glucose Tolerance Test (OGTT), in patients with impaired glucose tolerance and abdominal obesity.
    To assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 during 35 days.
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of GFT505 80mg compared with placebo in improving the VO2max.
    To describe the changes on others parameters measured during the physical exercise test (VCO2, RQ, lactate concentration...)
    To describe the changes of fasting glycaemia, insulinemia and HOMA index in the two groups. HOMA index is calculated as follow: [fasting serum glucose (mmol/l) X fasting insulin level (µunits/ml) /22,5].
    To describe the changes in TG, HDL-C, LDL-C and non-HDL-C levels in the two groups.
    To describe the changes in inflammatory markers and others parameters, in the two groups.
    To describe the changes in the circulating shed membrane microparticles (MP) signature
    To describe the changes in pedometer measurements (number of daily steps)
    To assess the plasma exposure of GFT505 after repeated once daily administrations of GFT505
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
    1) Provide written informed consent prior to enrolment.
    2) Male or post-menopausal female (defined as >12 months since last menstrual period and with stable (at least 6 months prior to screening) and continuous Hormonal Replacement Therapy or surgical menopause).
    3) Aged from 18 to 75 years. According to local regulations, Tunisian patients should be aged from 20 to 75 years.
    4) Waist circumference ≥94cm for male, ≥ 80cm for female.
    5) Fasting Plasma Glucose (FPG) between 110* and 126 mg/dl (between 6.1 and 7.0 mmol/l) within 6 months prior to the screening visit (documented in the patient file), and/or analysed the day after visit V1 (B1 lab).
    * a tolerance of 10% for the lower limit is authorised.
    6) Patients without previous experience of CVD**.
    ** Cardiovascular disease will be defined as:
    1) Peripheral Artery Disease
    a) Lower limb [history of acute leg ischemia or clinical symptoms of arteriopathy (intermittent claudication within 6 months preceding the study)]
    b) Peripheral carotid artery disease [history of stroke, TIA (Transient Ischemic Attack)]
    c) Abdominal aortic aneurysm
    2) Coronary Heart Disease (Angina pectoris, history of myocardial infarction, revascularisation procedures)

    7) Non-hypertensive or patient taking antihypertensive medication (except non-permitted medication) maintained at a stable dose for 2 months at least prior to screening (and the stable dose can be maintained throughout the study).
    8) Sedentary habits (patients not exercising more than 2 hours per week and not having occupational activity necessitating physical efforts).
    9) Patient agrees to come to following visits inside the protocol specified range

    In addition to the above criteria, all of the following inclusion criteria must be fulfilled at V2 (or results of B2 lab):
    10) 2-hour glycaemia at OGTT* (2hr after a 75g oral glucose load) ≥140 mg/dL (7.8 mmol/l) at B2 lab, taken from blood sample within 7 days before V2.
    * a tolerance of 10% is authorized
    11) Negative ECG stress test within the 12 months prior to the visit V1 (documented in the patient file) or performed between V1 and V2 visits, to exclude patients with contraindications to moderate-intensity exercise (underlying coronaropathy or arrythmmia).
    E.4Principal exclusion criteria
    Patients presenting with any of the following exclusion criteria will not be included in the trial:
    1) Body Mass Index (BMI) ≥ 40 kg/m².
    2) Weight change (variation >5%) within 6 months at least prior to screening.
    3) Known Heart Failure (Grade I to IV of NYHA classification).
    4) Blood Pressure > 160 / 95 mmHg.
    5) Known alcohol and/or any other drug abuse or dependence. Alcohol consumption of more than 3 alcoholic beverages per day is considered abusive. One alcoholic beverage is defined as 30 mL distilled spirits, 120 mL wine, or 330 mL beer.
    6) Known Type I or type II Diabetes Mellitus.
    7) Evidence of any other unstable or untreated clinically significant immunological, neoplastic, endocrine, haematological, gastrointestinal, neurological or psychiatric abnormalities or medical disease.
    8) Any serious medical condition that prevent participants from adhering to the protocol or performing the physical exercise test safely (ie. articular symptomatology or chronic respiratory disease)
    9) Evidence of any acute and chronic inflammatory processes
    10) Known homozygous familial hypercholesterolaemia or known Type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
    11) Patients who have serious or unstable medical or psychological conditions which, in the opinion of the Investigator, would lead the patient to be non-compliant or uncooperative during the study or would compromise the patient’s safety or successful participation in the study.
    12) Patients who have donated blood or blood products within the previous month prior to screening or who plan to donate blood or blood products at any time during the trial and in the 3 months following the end of the study.
    13) The Patient is a female of childbearing potential, is pregnant or lactating.
    14) Any medication that may interfere with study medication absorption, distribution, metabolism or excretion or could lead to induction or inhibition of microsomial enzymes within 3 months prior to the screening day.
    15) Patients having taken oral anti-diabetic drugs in the 3 months preceding randomisation visit.
    16) Concomitant treatment with drugs known to affect plasma lipid levels and plasma glucose levels.
    17) Currently taking other investigational drugs or who have taken part in a clinical trial within the previous month prior to screening.
    18) Known intolerance or contra-indication to the list of excipients of GFT505 (Gelatin, Lactose monohydrate, Titanium dioxide, Red Iron Oxide, Magnesium Stearate).
    19) Patient not covered by Health Insurance System and/or not in compliance with the recommendations of National Law in force.
    20) Patient who cannot be contacted in case of emergency.

    In addition to the above criteria, the patient should not present any of the following exclusion criteria at V2 (or results of B1 and B2 lab):
    21) Glycated haemoglobin (HbA1c) >7%
    22) Uncontrolled hypothyroidism defined as TSH > 2X the upper limit of normal (ULN). Thyroid dysfunction controlled for at least 6 months prior to screening is permitted.
    23) Significant renal disease, including nephritic syndrome, chronic renal failure (defined as creatinine clearance < 60 mL/mn according to Cockroft-Gault formula and serum creatinine >180 µmol/L).
    24) Active liver disease or hepatic dysfunction**** as defined by elevations in liver enzymes: [alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT)] >3X the upper limit of normal (ULN), and [alkaline phosphatases (ALP)]> 2X the upper limit of normal (ULN).
    **** Patients with NonAlcoholic SteatoHepatitis (NASH) will be allowed to participate in the study.
    25. Unexplained serum creatine phosphokinase (CPK) > 2X the upper limit of normal (ULN). Patients with a reason for CPK elevation may continue in screening and have the measurement repeated prior to randomization; a repeat CPK > 2X ULN is exclusionary.
    26) A fasting TG > 400mg/dl and a LDL-c > 220mg/dl
    27) Patient for whom the wash-out period of lipid-regulating drugs (fibrates, statins and other classes of lipid-regulating drugs) has not been respected or who has taken any non-permitted medication.
    E.5 End points
    E.5.1Primary end point(s)
    Primary Endpoint:
    - Change in plasma Glucose 2hr following oral glucose load from baseline (B2) to B4.

    Secondary Endpoints:
    - Change in VO2max at physical exercise test measured at baseline (V2) and V4.
    - Changes on others parameters measured during the physical exercise test (VCO2, RQ, lactate concentration...) at baseline (V2) and V4.
    - Changes in OGTT parameters (insulin AUC, glucose AUC) measured at baseline (B2) and B4.
    - Changes in fasting glycaemia and insulinemia from baseline (B2) to B4.
    - Changes from baseline (B2) to B4 in HOMA index.
    - Number of daily steps covered by patients at baseline visit (V2) and V4, measured by a pedometer.
    - Changes from baseline (B2) to B4 in lipids (LDL-C, non-HDL-C,TG, HDL-C, Total Cholesterol, calculated VLDL-C) and special lipids (Apo AI, Apo AII, Apo B, Apo CIII, Apo CIII/B, Apo CIII-nonB, ApoE/B, ApoE/non B, small dense LDL, remnants, FFA, Lp(a)).
    - Changes from baseline (B2) to B4 in inflammatory markers (hsCRP, TNF-alpha, IL-6, PAI-1, gene expression in leukocytes, amyloïd A serum, Lp-PLA2, ICAM, VCAM, adiponectin, leptin, AngPTL4), in renal function markers (alpha-1 microglobulin, beta-NAG, N-Gal, albumin, creatinin, microscopic analysis, beta-2-microglobulin and cystatin C), in oxidative stress markers (isoprostan).
    - Changes from baseline B2 to B4 for circulating MP signature.
    - SAE, AE, physical examination, vital signs, medical history, ECG.
    - Haematology (haemoglobin, haematocrit, RBC, WBC and differential count, platelet counts, haptoglobin, prothrombin, reticulocytes count) and biochemical markers [insulin, fasting plasma glucose, c-peptide, creatinine, creatinine clearance, total proteins, albumin, electrolytes (sodium, potassium, chloride, calcium), uric acid, urea, AST, ALT, GGT, alkaline phosphatases, CPK, total and conjugated bilirubin, troponin I, fibrinogen, homocystein, ProANP, ProBNP, TSH, HbA1c, fructosamin] and urinalysis.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the trial corresponds to the last patient last visit
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 40
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2009-04-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2009-05-28
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2009-12-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 12:27:31 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA